AstraZeneca, Firing On All Cylinders, Sets Aggressive R&D Goals
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K. drug maker flaunted its dramatically improved pipeline to investors Nov. 18, highlighting oncology specifically, a new “growth platform.” But will investors be persuaded to wait three years for growth?